CompletedPhase 3NCT00001305
Growth Hormone Therapy in Osteogenesis Imperfecta
Studying Osteogenesis imperfecta
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Principal Investigator
- Joan C Marini, M.D.Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Intervention
- Humatrope(drug)
- Enrollment
- 42 target
- Eligibility
- 3-16 years · All sexes
- Timeline
- 1991 – 2017
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00001305 on ClinicalTrials.govOther trials for Osteogenesis imperfecta
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07366086Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis ImperfectaAmgen
- RECRUITINGPHASE2NCT07062588Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)Angitia Incorporated Limited
- RECRUITINGNANCT07412782REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)Meyer Children's Hospital IRCCS
- RECRUITINGNANCT07478224An Interventional Study to Evaluate the Impact of Blood Flow Restriction Training on Muscle, Bone, and Quality of Life in Adults With Osteogenesis Imperfecta Type IUniversity Hospital, Ghent
- RECRUITINGNCT07287241Prospective Observational Cohort Study of Cardiac Structure and Function in Children and Adults With Osteogenesis ImperfectaIstituto Ortopedico Rizzoli
- ACTIVE NOT RECRUITINGPHASE3NCT06636071Setrusumab in Pediatric Japanese Subjects With Osteogenesis ImperfectaUltragenyx Pharmaceutical Inc
- RECRUITINGPHASE3NCT05972551Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis ImperfectaAmgen
- RECRUITINGNANCT05927389Adapted Physical Activity Program (APA) for Effort Rehabilitation of Children and Teenagers With Osteogenesis ImperfectaUniversity Hospital, Toulouse